There are eight subtypes of P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11
, P2Y12, P2Y13, and P2Y14), which are ubiquitously expressed in body, including the CNS .
Additionally, emerging studies showed that pharmacological targeting of ATP-gated purinergic P2 receptors (P2X1-7 and P2Y11
) can potentially modulate the generation of seizures, seizure-induced brain damage, and inflammatory processes [135-137].
Eight subtypes of P2Y have been identified to date--P2Y1, P2Y2, P2Y4, P2Y6, P2Y11
, P2Y12, P2Y13, and P2Y14--with differences in both pharmacology and downstream signalling pathways [3, 4].
(2008), demonstrated that P2Y2 and P2Y11
receptors were expressed in near-IR light irradiated normal human neural progenitor cells in vitro (33).
There are seven known P2X receptor subtypes (P2X1-7) and eight P2Y receptor subtypes (P2Y1, P2Y2, p2y4, P2Y6, P2Y11
, P2Y12, P2Y13, and P2Y14) .
ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11
At present, there are eight accepted P2Y receptors: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11
, P2Y12, P2Y13, and P2Y14 [8, 9].